U.S. Markets open in 2 hrs 1 mins

Amarin Corporation plc (AMRN)

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
3.49+0.04 (+1.16%)
At close: 4:00PM EDT
People also watch
  • If we can increase and stay at around $5 a share (half the Cantor evaluation) before Reduce-It results, that would be great!
  • Up after hours with volume
  • First 30 minutes of trade: volume exceeded average daily volume, price 3.55.
  • After hours trading at 16:30: 3.62 volume 104k+. Let's hope it keeps going and opens at after hours or premarket highs tomorrow. As was mentioned by another poster (I think it was Hawkeye), the last resistance level was 3.51.
  • Moving up on good volume. Hope this means something.
  • Target $10.00 will be achieved soon! What's the text consensus stock target?
  • Dang, half the normal volume in the first 15 minutes of trading....
  • What's the excitement about,,,,News or manipulation?
  • IGXT (MC $50 M) NDA filing for MEGA thin-flim Cialis (better than Viagra) this month =10++ BAGGER Potential ! PLEASE read this guys and then join us to make big money .A LIFETIME OPPORTUNITY HERE GUYS !!!

    2 US-NDA submission within 2 months ,lot of Cash and heavily underpriced at a valuation of just $50 million .1 Big drug partnered with Endo Pharma already under review by FDA market launch expected in 1H 2018 .GL

    Intelgenx (IGXT)

    MarketCap $50 Million
    Cash ~$12 Million (including convertible debt) =cash untill 2021+
    Price: 0.80

    NDA submission for tadalafil (erectile dysfunction) thin-film version of Blockbuster drug Cialis in June or July
    NDA resubmission for Rizaport (migraine) in early Q3
    Partnership for Tadalafil in 2H 2017


    IntelGenx previously confirmed the bioequivalence of Tadalafil to Eli Lilly’s Cialis, which had sales of $1.5-billion in 2016 but faces generic competition in 2020. IntelGenx has an exclusive license for oral films from Lilly for its dosing patent, which would allow Tadalafil to enter the ED market in the U.S. free from patent litigation from Lilly. Dr. Matzen explains that Tadalafil, which offers a discrete dosing alternative, could enter the market in 2018, with up to three years of market exclusivity before Cialis is hit with generic competition.

    Tadalafil is an erectile dysfunction (ED) treatment that boasts bioequivalence with Cialis, the current leading brand, and with a successful biostudy in-hand a 505(b)(2) NDA is set to be filed any day now, meaning that a full launch should be expected in mid-2018. Cialis is already winning-out over Viagra in terms of numbers of prescriptions, which is largely down to price and efficacy, but when Tadalafil comes to market with the same product in a more convenient and discreet delivery mechanism, IntelGenX should see a massive number of customers take-up its services.

    IntelGenx has multi-faceted BD approach for its oral films
    With a burgeoning pipeline of pharmaceutical oral films, IntelGenx’s (OTCQX:IGXT; TSXV:IGX) business development strategy is focused on partnering its product pipeline along with actively meeting with potential partners to explore manufacturing
  • End of quarter ramp ?
  • Monster MicroCaps SPECIAL ALERT to AMRN shareholders – NWBO $.19 and climbing, just announced $11 million financing with convertible debt payable in 3 years at $0.25, $.50 and $1.00. NWBO expected to release final Phase III Trial results any day from now until mid-July. If results are comparable to preliminary data, shares likely to explode to yield enormous percentage gains. Announcement could be huge because DCVax-L and DCVax Direct are also proven effective against 13 common cancers and has only mild fever as potential side effect. This breakthrough immunotherapy might replace the $100 Billion chemotherapy market.

    NWBio Closes 3-Year Convertible Debt Exchange and Financing, and Completes Payoff of Last $5 Million of 2014 Bonds
    This completes the Company's payoff of $11 million in principal amount of bonds, plus associated interest and forbearance fees, over the period from March through June of this year in accordance with an installment payment agreement with the bondhold
  • GREAT numbers following the short week! Thank you to Sam81 on the iHub boards for posting as usual.
    Scripts Update for Week Ending 09/06
    ATH in TRx & Refills Numbers & Market Share
    NRx Numbers & Market Share is 5th ATH
    TRx: 23,089 {vs 20,962; +10.15%} Sector +6.63% -- ATH
    NRx: 8,912 {vs 7,808; +14.14%} Sector +12.72%
    Ref: 14,177 {vs 13,154; +7.78%} Sector +3.26% -- ATH
    TRx: 55,032 {vs 52,169; +5.49%}
    NRx: 20,584 {vs 18,292; +12.53%}
    TRx: 1,393 {vs 1,436; -2.99%}
    NRx: 467 {vs 482; -3.11%}
    V TRx Market Share: 29.04% vs 28.11% -- ATH
    V NRx Market Share: 29.74% vs 29.37% -- {ATH = 30.22%}
    V Ref Market Share: 28.61% vs 27.41% -- ATH
  • $3.64 in premarket
  • Good read:


    Vascepa® (Icosapent Ethyl) Showed Reductions in Potentially Atherogenic Lipid Parameters in Statin-Treated Women With Type 2 Diabetes and Persistent High Triglycerides
  • Forming a wedge. Breakout coming.
  • Great results out today. Hoping for a good one today. Good luck to all Longs!
  • (AXSM) Market Cap $90 M/Cash $55 M / 5x BIG Phase 3 programs in various indications targeting large Markets with first results in Q3 2017 =20 BAGGER ..FANTASTIC OPPORTUNITY !

    Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $90 million and $55 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .

    This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL

    Axsome (AXSM)

    Market-Cap: $90 Million
    Cash: $55 Million(cash runway into the first quarter of 2019.)

    Shares Out: 23.5 Million

    Aegis Capital has reiterated a ‘Buy’ rating and price target of $20 on Axsome Therapeutics (NASDAQ: AXSM) after the company reported financial results for the quarter ended March 31, 2017. The analyst noted that although Axsome reported revenue in-line with consensus estimates, the focus remains on upcoming catalysts such as the company’s ongoing clinical trials. Since February 2017, the company’s AXS-05 has received fast track designation from the FDA for the treatment of Alzheimer’s disease (AD) agitation and treatment resistant depression (TRD). Topline data from the TRD treatment study is expected in the first quarter of 2018. Additionally, Axsome is developing AXS-02 in three separate phase 3 clinical programs, including chronic low back pain associated with modic changes and complex regional pain syndrome, with interim data expected in the fourth quarter of 2017, as well as knee osteoarthritis associated with bone marrow lesions, with interim data expected in the third quarter of 2017.
  • Weekly scripts update from Sam81 on the iHub boards:
    Scripts Update for Week Ending 05/26
    ATH in TRx & NRx Market Share
    TRx: 22,348 {vs 22,127; +1.00%} Sector +0.49%
    NRx: 8,842 {vs 8,856; -0.16%} Sector -1.63%
    Ref: 13,506 {vs 13,271; +1.77%} Sector +1.82%
    TRx: 53,506 {vs 53,441; +0.12%}
    NRx: 19,945 {vs 20,449; -2.46%}
    TRx: 1,393 {vs 1,306; +6.66%}
    NRx: 470 {vs 437; +7.55%}
    V TRx Market Share: 28.93% vs 28.78% -- ATH
    V NRx Market Share: 30.22% vs 29.78% -- ATH
    V Ref Market Share: 28.14% vs 28.16% -- (ATH = 28.16%)
  • Hope we get good news on Amarin later in the year. Check out Nexs. Stock up +77% today. Still way off 52 week high of
    .88. Could see higher highs when we get news out, hopefully soon. Sentiment on both AMRN and NEXS: Strong buy.
  • This stock is dead, it is only going to go down from here